General
Preferred name
NIMODIPINE
Synonyms
BAY-e 9736 ()
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate ()
BAY E 9736 ()
Nemotan ()
Nymalize ()
Periplum ()
BAY-E-9736 ()
NSC-758476 ()
Nimodipine ap ()
Nimotop ()
Admon ()
Nimodipine-d7 ()
P&D ID
PD000982
CAS
66085-59-4
1246815-36-0
Tags
available
drug
Approved by
FDA
First approval
1988
Drug Status
investigational
approved
Drug indication
Cerebral vasospasm
Vasodilator
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Nimodipine is a dihydropyridine calcium channel blocker. (GtoPdb)
MOA Although the precise mechanism of action is not known, nimodipine blocks intracellular influx of calcium through voltage-dependent and receptor-operated slow calcium channels across the membranes of myocardial, vascular smooth muscle, and neuronal cells. By specifically binding to L-type voltage-gated calcium channels, nimodipine inhibits the calcium ion transfer, resulting in the inhibition of vascular smooth muscle contraction. Evidence suggests that the dilation of small cerebral resistance vessels, with a resultant increase in collateral circulation, and/or a direct effect involving the prevention of calcium overload in neurons may be responsible for nimodipine's clinical effect in patients with subarachnoid hemorrhage.
DESCRIPTION Potent L-type Ca2+ channel antagonist (LOPAC library)
DESCRIPTION CaV1.x blocker (Tocris Bioactive Compound Library)
DESCRIPTION Ca2+ channel blocker (L-type) (Tocriscreen Total)
Cell lines
2
Organisms
8
Compound Sets
34
AdooQ Bioactive Compound Library
A10645
Cayman Chemical Bioactives
14573
30720
ChEMBL Approved Drugs
CHEMBL1428
ChEMBL Drugs
CHEMBL1428
Concise Guide to Pharmacology 2017/18
2523
Concise Guide to Pharmacology 2019/20
2523
Concise Guide to Pharmacology 2021/22
2523
Concise Guide to Pharmacology 2023/24
2523
DrugBank
DB00393
DrugBank Approved Drugs
DB00393
DrugCentral
1937
DrugCentral Approved Drugs
1937
DrugMAP
DMQ0RKZ
DrugMAP Approved Drugs
DMQ0RKZ
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
2523
JUMP-Target 1 Compound Set
4497
Ki Database
Nimodipine
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1428
Mcule NIBR MoA Box Subset
MCULE-4717687158
MedChem Express Bioactive Compound Library
HY-B0265
NCATS Inxight Approved Drugs
57WA9QZ5WH
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Nimodipine(Nimotop)
TargetMol Bioactive Compound Library
T0343
The Spectrum Collection
Tocris Bioactive Compound Library
0600
Tocriscreen Total
VGSC-DB
NA5927
External IDs
38
Properties
(calculated by RDKit )
Molecular Weight
418.17
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
2
Aromatic Ring Count
1
cLogP
2.97
TPSA
117.0
Fraction CSP3
0.43
Chiral centers
1.0
Largest ring
6.0
QED
0.3
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
L-type
Pathway
Endocrinology/Hormones
Membrane Transporter/Ion Channel
Metabolism
Autophagy
Neuronal Signaling
Target
AHR
Calcium Channel
Mineralocorticoid Receptor
CACNB4
Autophagy,Calcium Channel
Primary Target
CaV1.x Channels (L-type)
MOA
Blocker
Calcium channel inhibitor L-type
Member status
member
Therapeutic Class
Vasodilator Agents
VGSC Target
Nav1.9
Source data